HealthifyMe’s Subscription-Based Digital Wellness Strategy

Industry & Competitive Context

The India fitness app market reached USD 521.06 million in 2025 and is projected to reach USD 2,912.10 million by 2034, growing at a compound annual rate of 18.69 percent, driven by rising health consciousness, rapid smartphone penetration, and growing demand for personalized digital wellness solutions. A related market study places the broader India digital fitness and wellness platforms market at approximately USD 1.5 billion, noting that the segment is characterized by intense competition, with more than 250 platforms vying for user attention.

Within this landscape, HealthifyMe (rebranded as Healthify in 2024) has positioned itself as a digital-first, AI-and-human-coaching hybrid, distinct from its most prominent domestic rival. Cult.fit, formerly known as Cure.fit, was founded by Mukesh Bansal and Ankit Nagori and has built India’s largest organised fitness chain, operating around 580 centres across more than 50 cities, backed by investors including Zomato, Tata Digital, Temasek, and Accel. Cult.fit’s model is asset-heavy and omnichannel, spanning gyms, home fitness equipment, healthy meal delivery (Eat.fit), mental wellness (Mind.fit), and apparel (Cultsport); the company reported operating losses of ₹535 crore in FY24 despite revenue growth, with competition from digital-only fitness apps like Fittr and HealthifyMe adding further pressure on margins and market share. Earlier entrackr reporting similarly noted that HealthifyMe’s main competitors were Tata Digital-owned CureFit and GOQii, with streaming platforms such as Disney+ Hotstar and fitness YouTubers acting as indirect competition. The competitive set also includes global consumer health technology names; IMARC’s market mapping lists cult.fit, HealthifyMe, FITPASS, Squats Fitness, Nike, MyFitnessPal, Google (Fitbit), Samsung, Strava, and Azumio as the principal players shaping the category.

This asset-light-versus-asset-heavy divide is the defining strategic fault line of the Indian digital wellness category, and it frames every choice HealthifyMe has made about where to compete and how to monetize.

Brand Situation Prior to the AI-First Repositioning

HealthifyMe was launched by Tushar Vashisht, Sachin Shenoy, and Mathew Cherian in 2012, initially built around calorie tracking. Early reporting on the company’s Series A round described a premium subscription model starting at Rs 800 per month, alongside corporate wellness and healthcare programme revenue streams, with the company then growing at approximately 20 percent month-on-month and working with hospital networks such as Medanta, Apollo, and Manipal. The company’s financing history through the 2010s reflects a gradual scale-up: having closed an USD 18 million Series B round in November 2018, it went on to raise USD 75 million in a Series C round in July 2021 led by LeapFrog Investments and Khosla Ventures, taking total capital raised to over USD 100 million.

By the time of that Series C round, HealthifyMe described itself as India’s largest digital wellness platform, with more than 25 million users across 300 Indian cities and around 1,500 coaches, and said it was targeting USD 50 million in annual recurring revenue by the end of that year. Roughly a quarter of the company’s revenue came from outside India, including Singapore and Malaysia, reflecting an early push into Southeast Asia even before the subsequent United States expansion. The brand’s core assets at this stage were twofold: a large proprietary behavioural dataset (meal logs, coach-client conversations, and biometric tracking) and a hybrid delivery model combining software with human nutritionists and trainers, a structure that differentiated it from pure-tracking apps such as MyFitnessPal while avoiding the heavy fixed-asset burden of gym-based competitors.

Strategic Objective

Across its public statements and funding announcements, HealthifyMe’s leadership has articulated a consistent strategic objective: convert a large, low-monetization free user base into a defensible, recurring-revenue subscription business by using artificial intelligence to reduce the cost of delivering personalized human coaching at scale. CEO Tushar Vashisht summarized this logic at the time of the Series C round, stating that the company’s combination of AI and human empathy could deliver results in weight and lifestyle disease management “at a fraction of the cost possible today.”

This objective has evolved along two axes over time. The first is geographic: moving from an India/Southeast Asia base toward North America and Europe. The company’s October 2024 fundraising was explicitly framed around fuelling expansion into the US market and enhancing AI-driven nutrition and fitness coaching capabilities. The second is the mix of what is being monetized: moving from pure subscription coaching toward adjacent, higher-value health use cases, most recently chronic disease and pharmacologically assisted weight management. By December 2025, CEO Tushar Vashisht told Reuters that the company’s vision was “to be the world’s biggest patient support provider for all GLP [GLP-1 receptor agonist] companies in every market,” signalling a strategic pivot from general wellness coaching toward a more clinically adjacent, higher-ARPU segment of the market.

Campaign Architecture & Execution

HealthifyMe’s go-to-market architecture rests on a freemium funnel layered with an increasingly AI-mediated coaching product, rather than a single discrete marketing campaign. The architecture can be read as four overlapping product waves.

Wave one: the human-coach subscription core. 

The original commercial model connected users with nutritionists and trainers who reviewed progress and provided diet or fitness plans on a subscription basis, complemented by products such as HealthifySmart, which used AI-based technology to customize diet plans, and HealthifyCoach, built around live conversations with human coaches.

Wave two: the conversational AI layer. 

In 2017, HealthifyMe unveiled Ria, described at the time as the world’s first conversational AI-enabled nutritionist, developed under the codename “Project Amadeus” and trained on the company’s accumulated dataset of roughly 150 million tracked meals, more than 20 billion macro- and micronutrient data points, and some 10 million message exchanges between coaches and clients. At launch, Ria was positioned as functionally comparable to Siri and Google Assistant but specialized for nutrition, and access was initially restricted to subscription-plan holders, with the company stating a longer-term intent to extend Ria’s knowledge graph into adjacent services such as health, education, and finance.

Wave three: pandemic-driven product expansion. 

The COVID-19 lockdowns were a clear inflection point in both user acquisition and product breadth. HealthifyMe launched HealthifyStudio in mid-June 2020, a live group workout platform, after the app had already seen 50 percent growth in organic sign-ups and retention in May 2020 compared with the January-to-March quarter, and the startup achieved its highest-ever monthly revenue of roughly USD 1 million that same May. Alongside HealthifyStudio, the company introduced HealthifyPlus during the pandemic, targeting users managing chronic conditions such as diabetes, polycystic ovary syndrome, high cholesterol, and hypertension; together, HealthifySmart and HealthifyStudio already contributed around 25 percent of the company’s revenue by mid-2021. In January 2021, the company followed this with “FitFest 21,” described as Asia’s first virtual fitness festival, offering more than 200 live workouts, masterclasses, and cooking sessions, after the app’s user base had grown by four million during 2020 to surpass 17 million total downloads globally.

Wave four: the generative-AI and rebrand phase.

 In June 2023, the company raised a USD 30 million pre-Series D round led by LeapFrog Investments and Khosla Ventures, alongside FinnFund and Van Lanschot Kempen, explicitly earmarked to “supercharge” its mission using generative AI, augmenting Ria and introducing a generative-AI-powered coach-facing tool. That tool, “Coach Co-Pilot,” equips the company’s human coaching staff with generative AI capabilities to create tailored diet and fitness plans, and the company has cited a Stanford-affiliated study reporting a 70 percent increase in weight-loss effectiveness when AI and human coaching were combined. In 2024, the company carried this further by rebranding from HealthifyMe to Healthify and launching Ria 2.0, described as a multimodal, multilingual conversational AI coach, alongside a commercial partnership with Swiggy allowing users to order meals aligned with Ria’s dietary recommendations directly through the app. The company claimed this new version of Ria was 40 percent more accurate than its predecessor and capable of recognising more than one million distinct global foods.

Most recently, in December 2025 the company signed a partnership with Novo Nordisk’s India unit, launching a patient-support coaching programme for users prescribed Novo’s GLP-1 weight-loss therapies, which Vashisht described as the company’s first partnership of this kind with a drugmaker. He noted that this weight-loss initiative already accounted for a double-digit share of company revenue and was its fastest-growing offering, with the company’s global user base standing at roughly 45 million and its paid-subscriber base in the six-figure range, though the company declined to disclose a precise subscriber count.

Positioning & Consumer Insight

HealthifyMe’s underlying consumer insight, as expressed consistently by its leadership across a decade of press statements, is that structured nutrition and fitness guidance in India has historically been accessible only to a narrow, affluent slice of the population through in-person dietitians, trainers, or premium gym memberships. Founder Tushar Vashisht framed the company’s 2017 Ria launch around the goal of “making healthy living accessible for all,” explicitly describing a model where qualified nutritionists could serve a much larger population by working remotely and being augmented by AI. This cost-accessibility thesis was restated at the time of the 2021 Series C raise, when Vashisht argued that combining AI with human empathy could deliver weight and lifestyle-disease management outcomes “at a fraction of the cost possible today.

This positions HealthifyMe against Cult.fit’s more premium, in-person, aspirational-lifestyle brand on one axis, and against free-tier global trackers such as MyFitnessPal on the other, by claiming a middle position: AI-scaled personalization with real human accountability, priced as a mass-market subscription rather than either a boutique service or a purely self-serve app. The 2025 pivot toward GLP-1 patient support extends this insight into a new register: as pharmacological weight-loss treatment becomes more widely prescribed in India, the company is positioning its coaching layer as the adherence and lifestyle-support infrastructure around a drug therapy that patients would otherwise receive with minimal behavioural support.

Media & Channel Strategy

Verified public information on HealthifyMe’s channel strategy is limited largely to product distribution and commercial partnerships rather than paid media. The primary distribution channel has consistently been direct app-store acquisition; as early as its Series A period the company had already surpassed one million downloads on Google Play and had been recognised with Google Play’s “Top Developer Badge.” By January 2021, the company had crossed 17 million downloads globally, and had expanded its footprint into Malaysia and Singapore with localised offerings.

The company has also used commercial partnerships as a distribution and retention channel rather than relying solely on direct acquisition. Its 2024 tie-up with food delivery platform Swiggy integrated Ria’s dietary recommendations directly into Swiggy’s restaurant and Instamart grocery network, with Swiggy’s food marketplace CEO Rohit Kapoor stating that combining Ria’s AI-driven nutritional insights with Swiggy’s assortment would make access to healthy eating “available at the touch of a button.” Separately, the company has used its existing subscriber base as a distribution channel for adjacent health services, such as when it offered live vaccination alerts to a stated 4.1 million subscribers through more than 670 channels during the pandemic period. Its December 2025 Novo Nordisk partnership represents a further evolution of this channel logic: embedding the HealthifyMe coaching product inside a pharmaceutical patient-support pathway rather than acquiring users through conventional advertising.

Business & Brand Outcomes

Several outcomes have been publicly documented across HealthifyMe’s funding and press history, though the company has not disclosed a complete, audited financial picture at every stage.

Funding trajectory.

The company’s early funding included a USD 1 million angel round from Dubai-based investor Neelesh Bhatnagar and a Series A round of roughly USD 6 million (about Rs 40 crore) led by IDG Ventures India, Inventus Capital, and Blume Ventures. This was followed by an USD 18 million Series B round closed in November 2018, then the USD 75 million Series C round in July 2021 led by LeapFrog Investments and Khosla Ventures, joined by HealthQuad, Unilever Ventures, Elm (an entity of Saudi Arabia’s Public Investment Fund), Chiratae Ventures, Inventus Capital, and Sistema Asia Capital, taking cumulative funding past USD 100 million. A further USD 30 million pre-Series D round followed in June 2023, and in October 2024 the company raised USD 20 million in fresh capital as part of a USD 45 million equity round led by Khosla Ventures and LeapFrog Investments, with new participation from Claypond Capital, the family office of healthcare entrepreneur Dr Ranjan Pai. As of December 2025, the company stated it had raised USD 122 million in total funding to date.

User scale.

The company reported more than 25 million users across 300 Indian cities around the time of its 2021 Series C round, more than 40 million users by the time of its 2024 rebrand, and approximately 45 million global users as of December 2025, with its CEO stating that its paid-subscriber base was in the six-figure range without disclosing an exact figure.

Financial performance.

Independent financial data aggregation shows a mixed recent picture. For fiscal year 2024, HealthifyMe Wellness Private Limited reported total revenue of approximately ₹206.8 crore, a decline of around 10 percent from the prior fiscal year; total expenses of approximately ₹295.1 crore, down about 21 percent year-on-year; and a net loss (profit after tax) of approximately ₹88.3 crore, representing a 37 percent narrowing of losses compared with the previous fiscal year. This is broadly consistent with an earlier, separately sourced estimate that the company’s revenue in calendar year 2023 was approximately USD 28 million.

Employee liquidity event.

In August 2021, shortly after its Series C close, the company announced an ESOP and equity buyback programme worth USD 12 million (about Rs 90 crore), intended to provide liquidity to roughly 100 current and former team members, with early angel investors such as Gopal Srinivasan of TVS Capital Funds and Micromax reported to be receiving up to 15 times their original investment.

Recent commercial diversification.

As of December 2025, the company’s GLP-1-linked weight-loss coaching programme already accounted for a double-digit percentage share of revenue and was described by its CEO as the company’s fastest-growing offering, with India identified as an emerging battleground for obesity treatment ahead of the 2026 patent expiry of semaglutide, the active ingredient in Novo Nordisk’s Wegovy.

Strategic Implications

HealthifyMe’s trajectory illustrates several transferable principles for subscription-based digital health businesses operating in cost-sensitive, high-growth markets. First, the company’s repeated emphasis on using AI to compress the unit cost of human-coach-delivered services reflects a deliberate strategy to make a labour-intensive service model scalable without proportionally scaling headcount, a structural requirement in a market where free or low-cost alternatives are abundant and willingness to pay for standalone digital wellness remains limited. Second, the sequencing of product launches around external shocks and emerging categories, HealthifyStudio and HealthifyPlus during the pandemic, generative-AI tooling as large language models became commercially viable, and GLP-1 patient support as pharmacological weight-loss treatment scaled in India, suggests a pattern of opportunistic category-adjacent expansion layered onto a stable coaching core, rather than reliance on a single static product.

Third, the financial data available for FY24 (declining revenue alongside a narrowing net loss and falling total expenses) suggests a period of deliberate cost rationalisation rather than pure growth-at-all-costs expansion, which is consistent with the broader shift in Indian venture-backed consumer technology away from aggressive cash burn following the 2022-2023 funding slowdown. Fourth, the pivot toward pharmaceutical-company partnerships marks a meaningful repositioning away from a pure consumer-subscription model toward a hybrid model in which healthcare and pharmaceutical partners, not only individual subscribers, become a revenue source, a structural shift that merits close observation as more details become publicly available. Finally, the competitive contrast with Cult.fit’s asset-heavy, omnichannel model underscores a broader strategic choice point in digital wellness: whether durable differentiation comes from owning physical delivery infrastructure or from owning proprietary behavioural data and AI coaching capability. HealthifyMe’s public record indicates a consistent bet on the latter.

Discussion Questions

1. HealthifyMe has pursued an asset-light, AI-augmented coaching model while its principal domestic competitor, Cult.fit, has pursued an asset-heavy, omnichannel model including owned gyms. Under what market conditions does each approach create more durable competitive advantage, and what risks does each face as AI coaching tools become more commoditised?

2. The publicly reported FY24 financials show HealthifyMe’s revenue declining while its net loss narrowed and total expenses fell sharply. What strategic trade-offs might explain a company choosing to prioritise cost discipline over top-line growth at this stage of its lifecycle, and what signals would indicate whether this is a sustainable transition or a sign of stalling demand?

3. HealthifyMe’s partnership with Novo Nordisk positions its coaching service as adherence support for a pharmaceutical product rather than as a standalone wellness subscription. What are the strategic benefits and risks of a digital wellness company embedding itself within a pharmaceutical company’s go-to-market and patient-support infrastructure?

4. The company has repeatedly used large proprietary datasets, tracked meals, coach-client message logs, and nutrient data, as a stated foundation for its AI products, including Ria and Ria 2.0. How defensible is a data-driven moat of this kind in a category where competitors and new entrants (including global players) can potentially license or build comparable AI capability?

5. Given the limited public disclosure around subscriber counts, retention, and unit economics, what questions would you want answered before recommending further investment in HealthifyMe’s current strategy, and how would you prioritise obtaining that information if conducting real due diligence?